is still a burden in Indonesia. There were 2.293 of cases registered in 2016 with only 54% of succeeded treatment in 2014. This disease severity shown in various manifestation, including bacterial load and lesion form. Many research has mentioned the great role of CD4 T lymphocyte in representing these manifestations. However, measuring CD4 T lymphocyte is still beyond Indonesian clinical practice. This study aims to analyze whether the regularly done lymphocyte levels measurement has association with these disease severities for its role in managing the disease.
Methods: This study uses cross-sectional design and 99 subjects from consecutive sampling at the biggest centre of MDR TB in Indonesia during May-September 2017. Subjects were diagnosed by Xpert MTB/Rif.
The lymphocyte count and chest x-ray were conducted before treatment. Lymphocyte count was divided into 2 categories (normal, under normal) then its associations with bacterial load (positive, negative) and pulmonary lesion form (cavitary, no cavitary) were analyzed by chi-square using SPSS version 20.
Results: There were 54 males and 45 females in 41.9 AE 11.4 average of age. Majority of subjects has lymphocyte levels under normal (67.6%), +2 bacterial load (27.3%), no cavitary lesion (57.6%), and no diabetes (66.7%). Significant association of under normal lymphocyte level with positive bacterial load was found (P = 0.008) while cavitary lesion shows otherwise (P = 0.854). Therefore, the cross-tabulation shows there are proportional differences in each relation, which are 73.2% and 16.4% respectively.
Conclusion:
It is possible to use lymphocyte level as a representation of disease severity in bacterial load aspect. Not being the major determinant of cavitary formation might underlie its insignificant finding in association with pulmonary lesion form. Majority of subjects has under normal lymphocyte level which indicates that MDR TB patient encounters immunity problem. Therefore, it should be included in the focus when treating the patients. of the most common infectious disease worldwide, screening latent tuberculosis infection (LTBI) in high risk group and give preventive therapy is an important strategy. Three-month high-dose weekly isoniazid (H) and rifapentine (P) (3HP) are well-known for LTBI treatment in general population but the adherence and adverse effects (AE) of are not clear among kidney transplant candidates.
Methods:
We enrolled kidney transplant candidates in a tertiary referred centre in northern Taiwan and screened the LTBI status using QuantiFERON-Gold In-tube. We suggested those with positive LTBI status receive preventive therapy and monitored the adherence and AE.
Results: There were 23 kidney transplant candidates enrolled. Ten of them received 3HP and Thirteen received 9-month daily isoniazid (9H). The average age and sex were similar between the two groups. There were two (20%) in the 3HP group and six (46%) in the 9HP group discontinued the treatment (P = 0.192). The discontinuation reason was drug AE in 100% (n = 2) and in 17% (n = 1) in the 3HP and the 9HP groups, respectively (P = 0.035). For those without drug AE, the adherence was higher patients received 3HP than the 9H group (100% vs 58%, P = 0.035). In regard to the AEs, one (7%) patient in the 9H group had Grade 2 malaise and vomiting whereas eight (80%) in 3HP group had ≥ Grade 2 AEs (P < 0.001) including two with ≥Grade 3. Generalized 
